Purpose: A high frequency of head and neck squamous cell cancers (HNSCC) contain constitutively activated signal transducer and activator of transcription 3 (STAT3). To further elucidate the prognostic role of STAT3 in HNSCC, the expression pattern of STAT3 was correlated with outcome in two independent data sets.
Head and neck squamous cell cancer (HNSCC) is the sixth leading cause of cancer-related deaths worldwide. Despite advances in diagnosis and treatment, morbidity and mortality rates of patients with HNSCC remain high (1) . Advances in molecular biology have led to the identification of molecules that promote the malignant properties of tumor cells and induce resistance to chemotherapy and radiotherapy. Targeting these molecules has become a major goal in cancer therapy and may eventually increase cure rates.
The signal transducer and activator of transcription (STAT) proteins are transcription factors that have been implicated in signaling by oncoproteins, cytokine receptorassociated kinases, growth factor receptor tyrosine kinases, and nonreceptor tyrosine kinases, originally defined as the signaling mechanism for IFN receptors. After activation, STAT proteins dimerize and translocate to the nucleus, where they bind to DNA-response elements and alter the transcription of genes controlling normal cell functions such as growth, apoptosis, and differentiation (2) . Among the seven STAT members, STAT3 is particularly interesting due to its constitutive phosphorylation in several human cancers (3) , its essential role in cell transformation by the Src oncoprotein (4) , and its ability to induce malignant transformation (5) (6) (7) .
Constitutive activation of STAT3 has been described in HNSCC and is involved in deregulation of cell cycle, increased proliferation, and inhibition of apoptosis (8, 9) . STAT3 is activated frequently in matched tumor/normal mucosa samples from HNSCC patients compared with normal mucosa from patients without cancer (8) . Constitutive activation of STATs was detected in extracts from HNSCC cells and was dependent on transforming growth factor-induced activation of the epidermal growth factor receptor (EGFR) tyrosine kinase (9) .
Despite the diversity in STAT3 activation signals, all result in the translocation of STAT3 to the nucleus, where it is involved in the regulation of genes that promote the malignant phenotype. These findings suggest that activated STAT3 may provide a sensitive marker for detecting the activation of oncogenic signaling pathways (i.e., EGFR) and aid in the selection of treatment modalities that may result in more efficient eradication of disease.
Although the role of constitutive activation of STAT3 in head and neck carcinogenesis has been well documented, its prognostic value for patients with HNSCC has not been rigorously studied. Studies (10, 11) evaluating the prognostic significance of STAT3 are limited by the technical difficulties inherent in assessing pSTAT3 with conventional immunohistochemistry such as variability in immunohistochemical techniques, different methods of pathologist-based scoring, and the semiquantitative nature of the assay. To overcome this problem, a method of in situ automated quantitative analysis (AQUA) has been developed (12) , which allows measurements of protein expression within subcellular compartments that results in several directly proportional to the number of molecules expressed per unit area. Thus, we avoid biases introduced from the arbitrary cutoff points used in conventional immunohistochemistry studies while at the same time preserving spatial and morphologic information that techniques such as Western blotting lose.
In the present study, we hypothesized that assessment of nuclear STAT3 levels by AQUA would be a more reliable indicator of STAT3 activation status. We therefore determined the effect of nuclear STAT3 protein levels on patient outcome in two independent cohorts of patients with HNSCC.
Patients and Methods

Patient population
For cohort 1, inclusion criteria were histologically confirmed primary squamous cell carcinomas of the head and neck treated at Yale-New Haven Hospital and Aristotle University Hospital between 1992 and 2005, and therapy with either external beam radiotherapy or gross total surgical resection and postoperative radiotherapy (n = 102). Exclusion criteria included presentation with metastatic or recurrent disease or failure to receive a full course of radiation therapy. Patients with incomplete clinical-pathologic data or those lost to follow-up were also excluded. For cohort 2, patients with confirmed HNSCC (oral cavity, oropharynx, hypopharyx, or larynx) who were enrolled in an Early Detection Research Network-sponsored study and who underwent surgical resection with curative intent at the University of Pittsburgh Medical Center between 2000 and 2004 were considered for inclusion in this study (n = 161). Tumor specimens from 58 of these HNSCC patients, 50 with paired adjacent histologically normal adjacent mucosa, were used to construct a tissue microarray (TMA), using triplicate tissue cores. HNSCC tumors included in cohort 2 TMA did not differ significantly by tumor site, clinical stage, or patient gender or age from those HNSCC tumors not incorporated into the TMA. Tissues were collected under the auspices of a tissue bank protocol approved by the University of Pittsburgh Institutional Review Board.
TMA construction
Two TMAs were constructed: (a) a TMA consisting of tumors from patient cohort I was constructed at the Yale University Tissue Microarray Facility including 102 cases and (b) a TMA consisting of HNSCC tumors from patient cohort II including 58 cases. Following Institutional Review Board approval, the TMAs were constructed as previously described (13) . Tissue cores 0.6 mm in size were obtained from paraffin-embedded, formalin-fixed tissue blocks from the archives of the Yale University and Aristotle University of Thessaloniki Department of Pathology or from the University of Pittsburgh Head and Neck Department of Pathology. H&E-stained slides from all blocks were first reviewed by a pathologist to select representative areas of invasive tumor to be cored. The cores were placed on the recipient microarray block using a Tissue Microarrayer (Beecher Instrument). All tumors were represented with at least 2-fold redundancy. Previous studies (14) have shown that the use
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of TMAs containing one to two histospots provides a sufficiently representative sample for analysis by immunohistochemistry. Addition of a duplicate histospot, although not necessary, does provide marginally improved reliability (14) . Cores from human papillomavirus 16-positive SiHa cell lines fixed in formalin and embedded in paraffin were selected for positive controls and included in the cohort 1 array.
Quantitative immunofluorescent staining
TMAs were deparaffinized with xylene and stained as previously described (15) . Briefly, slides were rehydrated and antigen retrieval was achieved by pressure cooking for 20 min in citrate buffer (pH = 6). Slides were preincubated with 0.3% bovine serum albumin in 0.1 mol/L of TBS (pH 8) for 30 min at room temperature. Slides were then incubated with primary antibody to STAT3 (1:1,000, clone 124H6; Cell Signaling Technology) and a wide spectrum rabbit anti-cow cytokeratin antibody (1:100, Z0622; DAKO) at 4°C overnight. The STAT3 antibody has been extensively validated in previous studies using immunohistochemistry and Western blot analysis of neoplastic tissue and tumor cell lines. Subsequently, slides were incubated with Cy3-conjugated goat antirabbit secondary antibody (A11010; Molecular Probes) diluted 1:100 in mouse EnVision reagent (K4001; DAKO Corp.) for 1 h at room temperature. Cy5 directly conjugated to tyramide (FP117; Perkin-Elmer) at a dilution was used as the fluorescent chromagen for STAT3 detection. Cy5 (red) was used because it is well outside the green-orange spectrum of tissue autofluorescence. Prolong mounting medium (ProLong Gold, P36931; Molecular Probes) containing 4′,6-diamidino-2-phenylindole was used to identify nuclei.
Automated image acquisition and analysis
Automated image acquisition and analysis using automated in situ quantitative measurement of protein analysis (AQUA) has been previously described (12) . In brief, monochromatic, high-resolution (1,024 × 1,024 pixel; 0.5 μm) images were obtained of each histospot. We distinguished areas of tumor from stromal elements by creating a mask from the cytokeratin signal. 4′,6-Diamidino-2-phenylindole signal was used to identify nuclei and the cytokeratin signal was used to define cytoplasm. Overlapping pixels [to a 99% confidence interval (CI)] were excluded from both compartments. The signal (AQUA score) was scored on a normalized scale of 0 to 255 expressed as pixel intensity divided by the target area. AQUA scores for each subcellular compartment (nuclear and cytoplasmic STAT3) as well as the tumor mask were recorded. AQUA scores for duplicate tissue cores were averaged to obtain a mean score for each tumor.
Statistical analysis
Histospots containing <5% tumor as assessed by mask area (automated) were excluded from further analysis. The AQUA STAT3 score was assessed by tertiles. Progression-free n Low (n = 47)% High (n = 23)% P n Low (n = 25)% High (n = 12)% P 
Results
Clinical and pathologic variable analysis
In cohort 1, there were 70 patients with primary squamous cell carcinoma of the head and neck who met inclusion criteria and for whom we had complete STAT3 expression data. We excluded from the analysis 32 cases (among 102) missing STAT3 expression information. These cases did not differ from the ones included in the analysis with respect to patient gender, tumor site, TNM stage, histologic grade, PFS and OS as assessed by Fisher's exact test, and log-rank test, respectively. For cohort 2, 37 of the 58 arrayed HNSCC tumors were successfully evaluated for nuclear STAT3 levels using AQUA. Unsuccessful assessment was due to tumor core loss; cases with lost cores did not differ from successfully evaluated tumors with respect to all parameters. Of those tumors successfully evaluated for nuclear STAT3 protein expression, tumors with high versus intermediate/low nuclear STAT3 levels did not differ by patient gender, tumor TNM stage, or tumor site for cohort 1 or cohort 2 (Table 1) .
Quantitative immunohistochemistry for STAT3 protein expression
As visualized by fluorescent immunohistochemistry, STAT3 displayed mixed nuclear and cytoplasmic staining (Fig. 1) . Normalized AQUA scores for STAT3 expression in tumors ranged from 1 to 100. Nuclear, cytoplasmic, and tumor STAT3 expression followed a skewed distribution as expected for a cancer tissue biomarker (Supplementary Fig. S1 ). To assess for intratumor heterogeneity of STAT3 expression and control for reproducibility of the assay, we compared AQUA scores from redundant tumor cores and observed significant correlation (Supplementary Fig. S2 ; R = 0.89). AQUA scores in the nuclear compartment were averaged between the two histospots and final scores ranging from 3.92 to 97.92 were obtained for 70 patients.
Univariate survival analysis
Progression-free survival. The status of nuclear STAT3 expression was evaluated for association with PFS using the log-rank statistic to determine significance. High nuclear STAT3 expression is associated with superior PFS. Patients in cohort 1 with high nuclear STAT3 had a higher cumulative survival at 5 years compared with patients with intermediate or low STAT3. The cumulative PFS at 5 years was 75.2% for high nuclear STAT3 expressors versus 35.4% for others. The median PFS has not been reached and the mean PFS is 88.9 months for high expressors, compared with a median of 21.3 and mean of 46.7 months for those with intermediate or low nuclear STAT3 expression by Fig. 1 . Fluorescent immunohistochemistry for automated analysis (AQUA). A, cytokeratin was used to identify tumor. B, binary gating of cytokeratin expression created the tumor mask (white). C, pseudocolored colocalization image showing compartment assignment. Cytokeratin-Cy3 (green) was used to define the nonnuclear compartment; 4',6-diamidino-2-phenylindole (blue) was used to define the nuclear compartment. D, Cy5 (red) was used to identify STAT3. Original magnification, ×20. Fig. 2A) . As shown in Table 2 , this difference in PFS was significant (P = 0.012; log-rank test). For cohort 2, elevated nuclear expression of STAT3 was also associated with improved PFS (high STAT3: median, 81.0; mean, 60.3 months; low STAT3: median, 17.2; mean, 33.0 months; P = 0.035). A greater proportion of patients in cohort 2 with high nuclear STAT3 levels remained PFS compared with patients with intermediate or low nuclear STAT3 levels ( Table 2) .
AQUA (
Overall survival. The expression status of STAT3 was also evaluated for association with OS. Kaplan-Meier analysis showed that there was a significant correlation between high nuclear STAT3 expression and improved OS. Patients in cohort 1 with high nuclear STAT3 levels had significantly better OS (median not reached; mean, 119.9 months), whereas patients with intermediate or low nuclear STAT3 levels had a shorter OS (median, 32.3; mean, 57.3 months; P = 0.009; log-rank test). Patients with high nuclear STAT3 Fig. 2 . A, Kaplan-Meier survival curve comparing PFS estimation between low and high expressing nuclear STAT3 groups. Patients with high nuclear STAT3 expression exhibit a higher probability of PFS (cumulative PFS at 5 y, 75.2% versus 35.4%). B, Kaplan-Meier survival curve comparing OS estimation between low-and high-expressing nuclear STAT3 groups. Patients with high nuclear STAT3 expression exhibit a higher probability of OS (cumulative OS at 5 y, 72.4% versus 38.3%). (Fig.  2B) . A nonsignificant trend was observed for cohort 2: patients with high nuclear STAT3 levels had a higher cumulative survival at 5 years than patients with intermediate or low STAT3 levels, 68.8% and 51.4%, respectively.
Multivariable survival analysis
Using the Cox proportional hazards model, we carried out multivariable analysis to assess the prognostic value of nuclear STAT3 expression by AQUA for both PFS and OS in cohort 1. We included the following prognostic variables in the regression model: gender, TNM stage, and tumor grade and tumor site. After backward selection, the model for PFS including only STAT3 is chosen. A 77% decrease in risk of a progression-defining event was estimated for patients with STAT3 protein expression in the upper tertile [hazard ratio (HR), 0.23; 95% CI, 0.06-0.91; P = 0.037], which for OS corresponds to an 87% decrease in risk (HR, 0.13; 95% CI, 0.03-0.67; P = 0.014; Table 3 ). For cohort 2, although the number of events is small, the significant association is sustained for PFS (HR, 0.31; P = 0.044) whereas it is not for OS (HR, 0.54; P = not significant).
Discussion
To our knowledge, this is the first study to perform a quantitative assessment of nuclear STAT3 in head and neck cancer in association with patient prognosis. We used AQUA, a method that allows quantitative measurement of protein expression within subcellular compartments. Because activation of STAT3 signaling involves translocation to the nucleus, we hypothesized that assessment of nuclear STAT3 expression could act as a marker of activation of a STAT3-mediated signaling pathway. Our findings show higher nuclear STAT3 level is predictive of favorable clinical outcome. Furthermore, nuclear STAT3 was the only identified prognostic factor when adjusting for other commonly used prognostic markers and pathologic parameters.
We previously reported the prognostic effect of tyrosine-phosphorylated STAT3 immunoexpression on survival in two independent cohorts of patients with HNSCC and evaluated pSTAT3, transforming growth factor-α, EGFR, and gastrin-releasing peptide receptor expression in matched tumor and lymph node metastases in one of these cohorts (11) . Immunoexpression of Our finding that high levels of nuclear STAT3 are associated with better outcome in HNSCC is subject to numerous interpretations. Tumors that activate these pathways appear less aggressive than tumors that progress even in the absence of STAT3 activation, perhaps because the later rely on alternate pathways more tightly related to invasiveness or treatment resistance. Activated STAT3 in early-stage HNSCC may play a role in tumor development by sparing cells from apoptotic death or through cooperation with other oncogenes. In our cohorts, the majority of tumors were of advanced stage. Thus, at advanced stage, tumors probably become independent of STAT3-mediated signaling. An alternative explanation suggests that STAT3 functions as a tumor suppressor protein. STAT3 plays a pleomorphic role in signal transduction and it is possible that it functions as an oncoprotein or a tumor suppressor protein depending on the setting. In mouse mammary gland, STAT3 is activated both during the apoptotic phase and during the highly proliferative state of early pregnancy (17) . There are also several examples in which activated STAT3 seems to play a role in differentiation and promoting apoptosis (18) (19) (20) . Conditional knockout studies in murine models have shown that STAT3 function is essential in facilitating mammary gland involution by inducing extensive epithelial cell apoptosis through upregulating IGFBP-5 (18, 21, 22) . De La Iglesia et al. (23) reported that STAT3 plays a pro-oncogenic or tumor suppressive role in glioblastoma depending on the mutational profile of the tumor. Deficiency of PTEN triggers a cascade that inhibits STAT3 signaling in murine astrocytes and human glioblastoma tumors. Accordingly, PTEN knockdown induces efficient malignant transformation of astrocytes upon knockdown of the STAT3 gene. In contrast to the tumor suppressive function of STAT3 in the PTEN pathway, STAT3 forms a physical complex with the pro-oncogenic protein EGFRVIII in the nucleus and mediates EGFRVIIIinduced glial transformation. STAT3 may play a dual role in head and neck carcinogenesis depending on the genetic background of the tumor similar to glioblastoma.
Several studies in patients' samples in different sets of tumors have shown similar results to the present study. Dolled-Filhart et al. (22) reported that breast tumors with positive STAT3 nuclear expression had a significantly improved survival (P = 0.03) at 5 years of follow-up. Hsiao et al. (24) studied STAT3 and STAT5 expression patterns in relation to survival in nasopharyngeal cancer using immunohistochemistry. Strong intranuclear staining, or intranuclear and cytoplasmic staining, were noted in 31 of the 43 specimens classified as "positive" for significant constitutive STAT3 activation and in 32 of the 38 specimens classified as positive for significant constitutive STAT5 activation. The authors found that following radiotherapy, patients with constitutive STAT5 activation, or activation of both STAT3 and STAT5, had better PFS and OS than those without activated STAT5. Nuclear STAT3 staining was inversely correlated with the development of distant metastases in a cohort of prostate cancer patients treated with either radiotherapy alone or radiotherapy plus short-term androgen blockade (25) . To the contrary, STAT3 expression has been associated with worse outcome in several studies (26) (27) (28) .
One limitation of our study is that our assay cannot differentiate between phosphorylated and unphosphorylated nuclear STAT3. It is known that STAT3 can enter the nucleus independently of its phosphorylation state. Unphosphorylated STAT3 enters the nucleus by binding to distinct importins (29) . Although phosphorylation is not a prerequisite for STAT3 nuclear import, the requirement for phosphorylation for the transcriptional activity of STAT3 remains a controversial issue (5, 30, 31) . Yang et al. (31) reported that a STAT3 mutated on Tyr 705 retained its transcriptional activity but activated a different set of genes compared with wildtype STAT3. Nuclear phosphorylation of STAT3 by a nuclear tyrosine kinase has been reported in breast cancer and may represent an alternative STAT3 activation mechanism, contributing to its oncogenic potential (32) .
To conclude, the present study shows that nuclear STAT3 protein expression in the upper tertile as assessed by AQUA is associated with better PFS in two independent cohorts of patients with HNSCC. 
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